Elsevier

Clinical Immunology

Volume 182, September 2017, Pages 4-13
Clinical Immunology

Innate immunity in Sjögren's syndrome

https://doi.org/10.1016/j.clim.2017.04.003Get rights and content

Highlights

  • Sjögren's syndrome (SS) is characterized by innate immune hyperactivity.

  • Data suggest innate immune dysregulation is an early disease event in SS.

  • Innate immune activation contributes to local and systemic SS manifestations.

  • Therapeutics that target innate immunity will likely be efficacious in SS patients.

Abstract

Sjögren's syndrome (SS) is an autoimmune disease of exocrine tissue that primarily affects women. Although patients typically experience xerostomia and xerophthalmia, numerous systemic disease manifestations are seen. Innate immune hyperactivity is integral to many autoimmune diseases, including SS. Results from SS mouse models suggest that innate immune dysregulation drives disease and this is a seminal event in SS pathogenesis. Findings in SS patients corroborate those in mouse models, as innate immune cells and pathways are dysregulated both in exocrine tissue and in peripheral blood. We will review the role of the innate immune system in SS pathogenesis. We will discuss the etiology of SS with an emphasis on innate immune dysfunction. Moreover, we will review the innate cells that mediate inflammation in SS, the pathways implicated in disease, and the potential mechanisms governing their dysregulation. Finally, we will discuss emerging therapeutic approaches to target dysregulated innate immune signaling in SS.

Introduction

Sjögren's syndrome (SS) is a debilitating autoimmune disease in which the immune system targets exocrine gland tissue. Like many other autoimmune diseases, SS displays a strong female predilection [1]. The disease occurs in two forms: primary (pSS) and secondary (sSS). Patients with pSS often experience loss of salivary and lacrimal flow, and exhibit serious systemic disease manifestations as well [2]. In sSS, patients have a diagnosis of SS as well as another autoimmune connective tissue disease, such as lupus erythematosus (SLE) or rheumatoid arthritis (RA) [1]. Most patients with SS experience salivary hypofunction, and this can lead to rampant dental decay and difficulty in chewing and swallowing [3]. Currently, there are no approved therapies that address disease etiology and patient management is palliative.

Although the cause of SS remains poorly understood, it is characterized by exaggerated innate and adaptive immune responses. The adaptive immune system is comprised of B and T cells and has been studied extensively in SS [4], [5]. B and T cells are activated pathogenically, and abnormalities in both populations are seen in glandular tissue and systemically in SS mouse models and patients [6]. Specifically, alterations in normal CD4 + T helper subset ratios are observed [7], [8]. Activated T cells produce inflammatory cytokines that drive B cell differentiation and class switching. Numerous B cells abnormalities are found in SS patients. For example, SS patients have autoantibodies with diverse specificities and are at high risk of developing B cell lymphomas [4], [9], [10], [11]. Thus, the adaptive immune system is a key contributor to SS pathology.

The adaptive immune system is often activated by signals generated by the innate immune response. Innate immunity provides the “first line” of defense, and serves to recognize Pathogen-Associated Molecular Patterns (PAMPs). These microbial components are capable of eliciting rapid and robust inflammatory responses [12]. There are many different types of receptors that bind PAMPs, termed pattern recognition receptors (PRRs). Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) are examples of PRRs that are activated by PAMPs [13]. Initially, it was thought that PRRs were important only in pathogen defense [14]; however, host-derived molecules can also activate innate immunity, and this is an established disease mechanism in autoimmunity [15], [16], [17], [18]. While the innate immune system plays an important role in SS pathogenesis [19], [20], [21], [22], the way in which it is activated is poorly understood. This review will provide an overview of the role of innate immunity in disease initiation and the specific cells and pathways that contribute to innate activation in SS. In addition, we will discuss current therapeutic approaches to mitigate activation of innate immunity.

Section snippets

Innate immune activation in salivary tissue precedes the adaptive in SS mouse models

Since markers of early SS disease in humans are not well defined, mouse models are instrumental in establishing early events that mediate exocrine gland dysfunction in SS [23]. Microarray studies performed on the C57BL/6.NOD-Aec1Aec2 pSS mouse model prior to lymphocytic infiltration of the submandibular gland (SMG) and lacrimal tissue identified differential expression of numerous genes associated with innate immunity [24], [25], [26]. Studies in SMG tissue from these animals revealed

Genetic studies in pSS patients identify polymorphisms in innate immune genes

Although there is a need for continued genetic studies in SS patients, polymorphisms in genes associated with innate immunity are identified by several groups [28], [29], [30], [31], [32]. There are > 15 robust susceptibility loci identified for SS and many of these are shared with SLE [33]. Similar to SLE, patients with SS display increased expression of type I and type II IFN-regulated genes in both salivary tissue and peripheral blood [19], [30], [34], [35], [36], [37], [38]. While the

Evidence for activation of innate immunity by environmental stimuli

The innate immune system is activated by environmental insults and these likely play an important role in the initiation and progression of disease. Studies in SS patients suggest viral infection may contribute to disease initiation and chronicity, as cytomegalovirus (CMV), Epstein Barr virus (EBV), and hepatitis C virus (HCV) are implicated in SS pathogenesis [42], [43], [44], [45]. Corroborating work shows that some SS patients display an IFN gene signature (vide supra), and IFNα is secreted

Innate immune cells in SS disease

Many types of innate cells are implicated in SS. Inappropriate activation of innate immune pathways occurs within exocrine tissue as well as systemically [19], [27], [53]. DCs, macrophages, salivary epithelial gland cells (SGECs) and natural killer (NK) cells are among the best characterized innate cells in SS, and the role of these cells in disease is discussed below.

Toll-like receptors

TLRs are crucial for innate immune activation [14]. TLRs are upregulated in salivary tissue and peripheral blood from SS patients and mouse models [25], [77], [83], [84], [85], [86], [87]. Therefore, signals transduced by TLR ligation may represent a sustained event in SS pathogenesis. While several TLRs are dysregulated in SS, we will limit our discussion to those that are best characterized in this disease.

Therapeutic approaches targeting innate immunity may be efficacious

Many therapeutics that reduce activation of the innate immune response are currently in clinical trials for the treatment of RA, SLE, and inflammatory bowel disease (IBD) [95], [108], [143], [144], [145]. A summary of emerging innate immune drug targets, effects and study phase is provided in Table 1 [95], [144], [146], [147], [148], [149], [150], [151], [152], [153], [154], [155], [156], [157], [158]. Given the centrality of innate-driven inflammation in SS, inhibition of receptors and

Conclusion

In summary, the innate immune response is crucial for SS pathogenesis, as it is implicated in disease initiation, chronicity, and likely contributes to the development of B cell lymphomas. Numerous cell types in peripheral blood as well as in exocrine tissue participate in the hyperactive innate immune response in SS. Emerging data suggest that noncoding RNAs also mediate innate immune dysfunction in the context of SS. Therefore, therapeutics that target innate immune inflammation will likely

Acknowledgements

Funding for this study was provided by the University at Buffalo School of Dental Medicine Start-up Funds (JMK).

References (162)

  • S. Kivity et al.

    Infection and autoimmunity in Sjogren's syndrome: a clinical study and comprehensive review

    J. Autoimmun.

    (2014)
  • D. Zhou et al.

    Critical involvement of macrophage infiltration in the development of Sjögren's syndrome-associated dry eye

    Am. J. Pathol.

    (2012)
  • M.J. Barrera et al.

    Sjogren's syndrome and the epithelial target: a comprehensive review

    J. Autoimmun.

    (2013)
  • C.M. Van Itallie et al.

    Architecture of tight junctions and principles of molecular composition

    Semin. Cell Dev. Biol.

    (2014)
  • M.N. Manoussakis et al.

    The role of intrinsic epithelial activation in the pathogenesis of Sjogren's syndrome

    J. Autoimmun.

    (2010)
  • J.A. Hamerman et al.

    NK cells in innate immunity

    Curr. Opin. Immunol.

    (2005)
  • I.S. Schuster et al.

    TRAIL + NK cells control CD4 + T cell responses during chronic viral infection to limit autoimmunity

    Immunity

    (2014)
  • Y. Izumi et al.

    Characterization of peripheral natural killer cells in primary Sjogren's syndrome: impaired NK cell activity and low NK cell number

    J. Lab. Clin. Med.

    (2006)
  • M.N. Manoussakis et al.

    Salivary epithelial cells from Sjogren's syndrome patients are highly sensitive to anoikis induced by TLR-3 ligation

    J. Autoimmun.

    (2010)
  • L. Zheng et al.

    Expression of Toll-like receptors 7, 8, and 9 in primary Sjögren's syndrome

    Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod.

    (2010)
  • P. Szodoray et al.

    Distinct profiles of Sjögren's syndrome patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF

    Clin. Immunol.

    (2005)
  • M. Thien et al.

    Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches

    Immunity

    (2004)
  • C.G. Helmick et al.

    Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I

    Arthritis Rheum.

    (2008)
  • A.S. Malladi et al.

    Primary Sjogren's syndrome as a systemic disease: a study of participants enrolled in an international Sjogren's syndrome registry

    Arthritis Care Res.

    (2012)
  • J.M. Kramer

    Current concepts in Sjogren's syndrome and considerations for the dental practitioner

    N. Y. Dent. J.

    (2015)
  • A. Hansen et al.

    B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue

    Arthritis Res. Ther.

    (2007)
  • A. Ambrosi et al.

    Update on the immunobiology of Sjogren's syndrome

    Curr. Opin. Rheumatol.

    (2015)
  • C.P. Mavragani et al.

    Sjogren's syndrome

    Annu. Rev. Pathol.

    (2014)
  • D.I. Mitsias et al.

    The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome

    Clin. Exp. Immunol.

    (2002)
  • G.E. Katsifis et al.

    T lymphocytes in Sjogren's syndrome: contributors to and regulators of pathophysiology

    Clin. Rev. Allergy Immunol.

    (2007)
  • A. Hansen et al.

    Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome

    Arthritis Rheum.

    (2004)
  • A. Hansen et al.

    Comparison of immunoglobulin heavy chain rearrangements between peripheral and glandular B cells in a patient with primary Sjögren's syndrome

    Scand. J. Immunol.

    (2003)
  • J. Liu et al.

    Cellular and molecular regulation of innate inflammatory responses

    Cell. Mol. Immunol.

    (2016)
  • K. Moreth et al.

    The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis

    J. Clin. Invest.

    (2010)
  • S. Bhattacharyya et al.

    FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling

    Sci. Transl. Med.

    (2014)
  • K. Midwood et al.

    Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease

    Nat. Med.

    (2009)
  • J.E. Gottenberg et al.

    Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome

    Proc. Natl. Acad. Sci. U. S. A.

    (2006)
  • C.J. Lessard et al.

    Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren's syndrome

    Nat. Genet.

    (2013)
  • H.Z. Low et al.

    Aspects of innate immunity in Sjögren's syndrome

    Arthritis Res. Ther.

    (2011)
  • T.N. Lavoie et al.

    Current concepts: mouse models of Sjögren's syndrome

    J. Biomed. Biotechnol.

    (2011)
  • C.Q. Nguyen et al.

    Differential gene expression in the salivary gland during development and onset of xerostomia in Sjögren's syndrome-like disease of the C57BL/6.NOD-Aec1Aec2 mouse

    Arthritis Res. Ther.

    (2009)
  • J.A. Ice et al.

    Genetics of Sjögren's syndrome in the genome-wide association era

    J. Autoimmun.

    (2012)
  • E.S. Emamian et al.

    Peripheral blood gene expression profiling in Sjögren's syndrome

    Genes Immun.

    (2009)
  • S. Rusakiewicz et al.

    NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome

    Sci. Transl. Med.

    (2013)
  • S.L. Musone et al.

    Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases

    Genes Immun.

    (2011)
  • M. Teruel et al.

    Genetics of systemic lupus erythematosus and Sjogren's syndrome: an update

    Curr. Opin. Rheumatol.

    (2016)
  • U. Båve et al.

    Activation of the type I interferon system in primary Sjögren's syndrome: a possible etiopathogenic mechanism

    Arthritis Rheum.

    (2005)
  • T.O. Hjelmervik et al.

    Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects

    Arthritis Rheum.

    (2005)
  • J.C. Hall et al.

    Molecular subsetting of interferon pathways in Sjogren's syndrome

    Arthritis Rheum.

    (2015)
  • J.C. Hall et al.

    Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases

    Proc. Natl. Acad. Sci. U. S. A.

    (2012)
  • Cited by (0)

    1

    Current address: Immco Diagnostics Inc., 60 Pineview Drive, Amherst, NY, United States.

    View full text